According to final Overall Survival (OS) results from the Phase 3 FLAURA2 Trial, first-line Osimertinib plus chemotherapy significantly improved OS in comparison with Osimertinib monotherapy for patients with EGFR-mutated non-small cell lung cancer (NSCLC).
David Planchard, MD, PhD, of the Institut Gustave Roussy, presented the final OS results during the first Presidential Symposium of the International Association for the Study of Lung Cancer (IASLC) 2025 World Conference on Lung Cancer. In the phase 3, open-label trial, they included 557 patients with NSCLC who harbored exon 19 deletions ot L858R mutations in EGFR. Those who enrolled had previously Untreated advanced or metastatic NSCLC with a WHO performance status of 0 or 1. The ones with stable central nervous system metastases were permitted to enroll in the FLAURA2 Trial. This global, randomized FLAURA2 Trial evaluated whether adding pemetrexed plua cisplatin ot carboplatin to Osimertinib could provide additional survival benefit.
“These compelling overall survival results confirm osimertinib plus chemotherapy as a first-line standard of care for patients with EGFR-mutated advanced NSCLC,” Dr. Planchard said in a news release from the IASLC. “By combining osimertinib with chemotherapy, we are able to extend survival for these patients while maintaining a manageable safety profile.”
In this trial, the median OS was 47.5 months for patients receiving osimertinib plus chemotherapy, nearly which is about 10 months longer than the median OS of 37.6 months with osimertinib monotherapy. Also, the 36-month survival rate was 63% among those receiving combination therapy as compared to 51% anong those receiving monotherapy. The officials said that the OS benefit was consistent across predefined subgroups. The final OS benefits from the FLAURA2 Trial reinforce osimertinib as the backbone therapy in this setting and with addition of chemotherapy offers a meaningful OS advantage for patients with advanced NSCLC.
The information shared in this blog is for educational purposes only. You should always consult with your healthcare provider for any medical needs.
Subscribe to our newsletter or follow us on Facebook or X today to stay informed and never miss an update!